The immunogenetics of Psoriasis: A comprehensive review.

[1]  Pui-Yan Kwok,et al.  Genome-wide scan reveals association of psoriasis with IL-23 and NFB pathways , 2016 .

[2]  A. Gottlieb,et al.  Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial , 2015, The British journal of dermatology.

[3]  H. Kittler,et al.  Clinical improvement in psoriasis with specific targeting of interleukin-23 , 2015, Nature.

[4]  X. Estivill,et al.  Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility , 2015, Nature Communications.

[5]  A. Santos-Silva,et al.  A specific molecular signature for psoriasis and eczema. , 2015, Annals of translational medicine.

[6]  Liangdan Sun,et al.  Whole-exome SNP array identifies 15 new susceptibility loci for psoriasis , 2015, Nature Communications.

[7]  M. Hafner,et al.  Laser capture microdissection followed by next‐generation sequencing identifies disease‐related microRNAs in psoriatic skin that reflect systemic microRNA changes in psoriasis , 2015, Experimental dermatology.

[8]  Min Liu,et al.  SRSF1 Facilitates Cytosolic DNA-Induced Production of Type I Interferons Recognized by RIG-I , 2015, PloS one.

[9]  C. Wallace,et al.  Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis , 2015, Nature Communications.

[10]  Wan-Wan Lin,et al.  Syk mediates IL-17-induced CCL20 expression by targeting Act1-dependent K63-linked ubiquitination of TRAF6. , 2015, The Journal of investigative dermatology.

[11]  C. Leonardi,et al.  Humanized anti-IFN-γ (HuZAF) in the treatment of psoriasis. , 2015, The Journal of allergy and clinical immunology.

[12]  A. Bowcock,et al.  CARD14 Expression in Dermal Endothelial Cells in Psoriasis , 2014, PloS one.

[13]  Sen Guo,et al.  A single-nucleotide polymorphism of miR-146a and psoriasis: an association and functional study , 2014, Journal of cellular and molecular medicine.

[14]  A. Pivarcsi,et al.  Genetic polymorphisms altering microRNA activity in psoriasis – a key to solve the puzzle of missing heritability? , 2014, Experimental dermatology.

[15]  Vinod Chandran,et al.  Fine Mapping Major Histocompatibility Complex Associations in Psoriasis and Its Clinical Subtypes , 2014, American journal of human genetics.

[16]  Y. Modis,et al.  Pattern Recognition and Signaling Mechanisms of RIG-I and MDA5 , 2014, Front. Immunol..

[17]  Fabian J Theis,et al.  Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema , 2014, Science Translational Medicine.

[18]  M. Feolo,et al.  HLA Diversity in the 1000 Genomes Dataset , 2014, PloS one.

[19]  S. Ambs,et al.  Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression , 2014, Proceedings of the National Academy of Sciences.

[20]  Y. Wasfi,et al.  Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. , 2014, The Journal of allergy and clinical immunology.

[21]  F. Nestle,et al.  The IL-23/IL-17 axis in psoriatic arthritis. , 2014, Autoimmunity reviews.

[22]  Mayte Suárez-Fariñas,et al.  Immunology of psoriasis. , 2014, Annual review of immunology.

[23]  M. Schön,et al.  c-Rel downregulation affects cell cycle progression of human keratinocytes. , 2014, The Journal of investigative dermatology.

[24]  J. Blander,et al.  Sensing Microbial RNA in the Cytosol , 2013, Front. Immunol..

[25]  R. Henschler,et al.  Aberrant epigenetic regulators control expansion of human CD34+ hematopoietic stem/progenitor cells , 2013, Frontiers in Genetics.

[26]  S. Sano,et al.  Epidermal hyperplasia induced by Raf-MAPK signaling requires Stat3 activation. , 2013, Journal of dermatological science.

[27]  J. Schmid,et al.  The complexity of NF-κB signaling in inflammation and cancer , 2013, Molecular Cancer.

[28]  F. Abad‐Santos,et al.  Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases , 2013, The Pharmacogenomics Journal.

[29]  G. Vena,et al.  Cyclosporine Regimens in Plaque Psoriasis: An Overview with Special Emphasis on Dose, Duration, and Old and New Treatment Approaches , 2013, TheScientificWorldJournal.

[30]  J. Krueger,et al.  IL-17 targeted therapies for psoriasis , 2013, Expert opinion on investigational drugs.

[31]  K. Odunsi,et al.  Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling , 2013, The Journal of experimental medicine.

[32]  C. Johansen,et al.  Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3‐Ser727 phosphorylation as a modulator of transcriptional activity , 2013, Experimental dermatology.

[33]  Y. E. Chen,et al.  Zc3h12c inhibits vascular inflammation by repressing NF-κB activation and pro-inflammatory gene expression in endothelial cells. , 2013, The Biochemical journal.

[34]  P. Muranski,et al.  Essentials of Th17 cell commitment and plasticity. , 2013, Blood.

[35]  A. Gottlieb,et al.  NF-κB: an essential transcription factor in psoriasis. , 2013, Journal of dermatological science.

[36]  James T. Elder,et al.  Identification of fifteen new psoriasis susceptibility loci highlights the role of innate immunity , 2012, Nature Genetics.

[37]  W. Busse,et al.  Genome-wide association studies of asthma indicate opposite immunopathogenesis direction from autoimmune diseases. , 2012, The Journal of allergy and clinical immunology.

[38]  B. Aneskievich,et al.  Emerging roles for TNIP1 in regulating post-receptor signaling. , 2012, Cytokine & growth factor reviews.

[39]  A. Bowcock,et al.  PSORS2 is due to mutations in CARD14. , 2012, American Journal of Human Genetics.

[40]  James T. Elder,et al.  Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. , 2012, American journal of human genetics.

[41]  Christian Gieger,et al.  Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. , 2012, American journal of human genetics.

[42]  A. Yoshimura,et al.  SOCS, Inflammation, and Autoimmunity , 2011, Front. Immun..

[43]  James T. Elder,et al.  TNFAIP3 Gene Polymorphisms Are Associated with Response to TNF Blockade in Psoriasis , 2011, The Journal of investigative dermatology.

[44]  Alan Menter,et al.  A subset of methylated CpG sites differentiate psoriatic from normal skin , 2011, The Journal of investigative dermatology.

[45]  Matti Pirinen,et al.  Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity , 2012 .

[46]  Anthony M Flores,et al.  TNIP1 is a corepressor of agonist-bound PPARs. , 2011, Archives of biochemistry and biophysics.

[47]  P. D. de Bakker,et al.  Genome‐wide meta‐analysis identifies novel multiple sclerosis susceptibility loci , 2011, Annals of neurology.

[48]  J. O’Shea,et al.  Helper T-cell Differentiation and Plasticity: Insights from Epigenetics Introduction , 2022 .

[49]  M. Simpson,et al.  Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. , 2011, American journal of human genetics.

[50]  A. Smahi,et al.  Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. , 2011, The New England journal of medicine.

[51]  C. Dong,et al.  Signaling of interleukin-17 family cytokines in immunity and inflammation. , 2011, Cellular signalling.

[52]  Richard C Trembath,et al.  Functional analysis of the RNF114 psoriasis susceptibility gene implicates innate immune responses to double-stranded RNA in disease pathogenesis. , 2011, Human molecular genetics.

[53]  D. de Ridder,et al.  Narrowband ultraviolet B inhibits innate cytosolic double‐stranded RNA receptors in psoriatic skin and keratinocytes , 2011, The British journal of dermatology.

[54]  K. Peris,et al.  The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans , 2011, PloS one.

[55]  P. Vito,et al.  Alternative Splicing of CARMA2/CARD14 Transcripts Generates Protein Variants With Differential Effect on NF-κB Activation and Endoplasmic Reticulum Stress-Induced Cell Death , 2011, Journal of cellular physiology.

[56]  Tomoki Chiba,et al.  Interplay of transcription factors in T‐cell differentiation and function: the role of Runx , 2011, Immunology.

[57]  Cisca Wijmenga,et al.  A Meta-Analysis of Genome-Wide Association Scans Identifies IL18RAP, PTPN2, TAGAP, and PUS10 As Shared Risk Loci for Crohn's Disease and Celiac Disease , 2011, PLoS genetics.

[58]  Xin Lin,et al.  NF-κB signaling pathways regulated by CARMA family of scaffold proteins , 2011, Cell Research.

[59]  P. Kwok,et al.  Carriers of rare missense variants in IFIH1 are protected from psoriasis. , 2010, The Journal of investigative dermatology.

[60]  R. Stephens,et al.  Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. , 2010, The Journal of clinical investigation.

[61]  Christian Gieger,et al.  Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2 , 2010, Nature Genetics.

[62]  James T. Elder,et al.  Association analyses identify six new psoriasis susceptibility loci in the Chinese population , 2010, Nature Genetics.

[63]  Christian Gieger,et al.  Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis , 2010, Nature Genetics.

[64]  Matti Pirinen,et al.  A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1 , 2010, Nature Genetics.

[65]  Christian Gieger,et al.  Genome-wide association analysis identifies three psoriasis susceptibility loci , 2010, Nature Genetics.

[66]  S. Kotenko,et al.  Interferon-lambda: a new addition to an old family. , 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[67]  Luis Puig,et al.  Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. , 2010, The Journal of investigative dermatology.

[68]  Jing Cui,et al.  Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci , 2010, Nature Genetics.

[69]  A. Blauvelt,et al.  Circulating Th17, Th22, and Th1 cells are increased in psoriasis. , 2010, The Journal of investigative dermatology.

[70]  James T. Elder,et al.  Genome-wide association study identifies a psoriasis susceptibility locus at TRAF 3 IP 2 , 2010 .

[71]  M. Daly,et al.  Genetic variants at CD28, PRDM1, and CD2/CD58 are associated with rheumatoid arthritis risk , 2009, Nature Genetics.

[72]  Ying Wang,et al.  Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus , 2009, Nature Genetics.

[73]  A. Fisher,et al.  Runx proteins regulate Foxp3 expression , 2009, The Journal of experimental medicine.

[74]  T. Nomura,et al.  Indispensable role of the Runx1-Cbfbeta transcription complex for in vivo-suppressive function of FoxP3+ regulatory T cells. , 2009, Immunity.

[75]  M. Gilliet,et al.  Self-RNA–antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8 , 2009, The Journal of experimental medicine.

[76]  A. Yoshimura.  Regulation of cytokine signaling by the SOCS and Spred family proteins. , 2009, The Keio journal of medicine.

[77]  F. Nestle,et al.  The IL-23/Th17 axis in the immunopathogenesis of psoriasis. , 2009, The Journal of investigative dermatology.

[78]  Lisa C. Zaba,et al.  Resident and "inflammatory" dendritic cells in human skin. , 2009, The Journal of investigative dermatology.

[79]  T. Mcclanahan,et al.  The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivo , 2009, Nature Immunology.

[80]  Wei Huang,et al.  Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21 , 2009, Nature Genetics.

[81]  Pui-Yan Kwok,et al.  Genomewide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways , 2008, Nature Genetics.

[82]  David Altshuler,et al.  Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus , 2008, Nature Genetics.

[83]  B. Suarez-Alvarez,et al.  NKG2D ligands: key targets of the immune response. , 2008, Trends in immunology.

[84]  Yihong Yao,et al.  Type I Interferon: Potential Therapeutic Target for Psoriasis? , 2008, PloS one.

[85]  Stefan Jenisch,et al.  Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. , 2008, The Journal of investigative dermatology.

[86]  L. van der Fits,et al.  IFN-alpha enhances poly-IC responses in human keratinocytes by inducing expression of cytosolic innate RNA receptors: relevance for psoriasis. , 2008, The Journal of investigative dermatology.

[87]  David S Sanders,et al.  Newly identified genetic risk variants for celiac disease related to the immune response , 2008, Nature Genetics.

[88]  M. Fu,et al.  A Novel CCCH-Zinc Finger Protein Family Regulates Proinflammatory Activation of Macrophages* , 2008, Journal of Biological Chemistry.

[89]  M. Leppert,et al.  Variants in the 5q31 cytokine gene cluster are associated with psoriasis , 2008, Genes and Immunity.

[90]  T. Michiels,et al.  IFN-Lambda (IFN-λ) Is Expressed in a Tissue-Dependent Fashion and Primarily Acts on Epithelial Cells In Vivo , 2008, PLoS pathogens.

[91]  S. Ghosh,et al.  Shared Principles in NF-κB Signaling , 2008, Cell.

[92]  Hua Yu,et al.  Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity1 , 2007, The Journal of Immunology.

[93]  T. Nomura,et al.  Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1 , 2007, Nature.

[94]  James G. Krueger,et al.  Pathogenesis and therapy of psoriasis , 2007, Nature.

[95]  T. Imaizumi,et al.  Cytokine modulation of retinoic acid-inducible gene-I (RIG-I) expression in human epidermal keratinocytes. , 2007, Journal of dermatological science.

[96]  Anjana Rao,et al.  Transcription factors T-bet and Runx3 cooperate to activate Ifng and silence Il4 in T helper type 1 cells , 2007, Nature Immunology.

[97]  Steven J. Schrodi,et al.  A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. , 2007, American journal of human genetics.

[98]  N. Perkins,et al.  Integrating cell-signalling pathways with NF-kappaB and IKK function. , 2007, Nature reviews. Molecular cell biology.

[99]  Pallavur Sivakumar,et al.  Interleukin‐29 uses a type 1 interferon‐like program to promote antiviral responses in human hepatocytes , 2006, Hepatology.

[100]  Antonio Leonardi,et al.  ABIN-1 Binds to NEMO/IKKγ and Co-operates with A20 in Inhibiting NF-κB* , 2006, Journal of Biological Chemistry.

[101]  James T. Elder.  PSORS1: linking genetics and immunology. , 2006, The Journal of investigative dermatology.

[102]  Antonio Leonardi,et al.  ABIN-1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-kappaB. , 2006, The Journal of biological chemistry.

[103]  R. Steinman,et al.  Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[104]  A. Bowcock.  The genetics of psoriasis and autoimmunity. , 2005, Annual review of genomics and human genetics.

[105]  A. Gottlieb,et al.  Differential Expression of Phosphorylated NF-κB/RelA in Normal and Psoriatic Epidermis and Downregulation of NF-κB in Response to Treatment with Etanercept , 2005 .

[106]  A. Gottlieb,et al.  Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. , 2005, The Journal of investigative dermatology.

[107]  A. Bowcock,et al.  Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. , 2004, Trends in immunology.

[108]  Yudong D. He,et al.  T lymphocyte activation gene identification by coregulated expression on DNA microarrays. , 2004, Genomics.

[109]  L. van der Fits,et al.  In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. , 2004, The Journal of investigative dermatology.

[110]  Jurg Ott,et al.  A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis , 2003, Nature Genetics.

[111]  R. Rottapel,et al.  Regulation of cytokine receptor signaling by SOCS1 , 2003, Immunological reviews.

[112]  Mark Lebwohl,et al.  Psoriasis , 1906, The Lancet.

[113]  T. Mcclanahan,et al.  A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R1 , 2002, The Journal of Immunology.

[114]  G. Krueger,et al.  Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. , 2001, The New England journal of medicine.

[115]  M. Nevalainen,et al.  Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer , 2001, Urological Research.

[116]  J Wagner,et al.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. , 2000, Immunity.

[117]  R. Contreras,et al.  The Zinc Finger Protein A20 Inhibits TNF-induced NF-κB–dependent Gene Expression by Interfering with an RIP- or TRAF2-mediated Transactivation Signal and Directly Binds to a Novel NF-κB–inhibiting Protein ABIN , 1999, The Journal of cell biology.

[118]  U. Engelmann,et al.  Selective expression of inducible nitric oxide synthase in human prostate carcinoma , 1998, Cancer.

[119]  U. Gubler,et al.  Differential Associations between the Cytoplasmic Regions of the Interleukin-12 Receptor Subunits β1 and β2 and JAK Kinases* , 1997, The Journal of Biological Chemistry.

[120]  U. Gubler,et al.  Differential associations between the cytoplasmic regions of the interleukin-12 receptor subunits beta1 and beta2 and JAK kinases. , 1997, The Journal of biological chemistry.

[121]  James G. Krueger,et al.  Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis , 1995, Nature Genetics.

[122]  P. Itin,et al.  The type I interferon system is locally activated in psoriatic lesions. , 1994, Journal of interferon research.

[123]  K. Wuepper,et al.  Psoriasis vulgaris: a genetic approach. , 1990, The Journal of investigative dermatology.

[124]  L. Nanney,et al.  Altered [125I]epidermal growth factor binding and receptor distribution in psoriasis. , 1986, The Journal of investigative dermatology.

[125]  W. Mueller,et al.  Cyclosporin A for psoriasis. , 1979, The New England journal of medicine.